Access cutting-edge uveal melanoma treatment through this clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.
Access uveal melanoma specialists in Philadelphia at no cost
This study follows strict safety protocols and ethical guidelines
All study-related uveal melanoma treatment provided free
This phase II trial tests how well tebentafusp works to shrink tumors prior to primary treatment with surgery or radiation in patients with uveal (eye) melanoma that has spread to nearby tissue or lymph nodes (locally advanced) or that cannot be removed by surgery (unresectable). Tebentafusp is a drug that binds to melanoma tumor cells as well as immune cells called T-cells. This binding causes an immune response against the melanoma cells, which leads to tumor cell death. Tebentafusp has been a
Sponsor: Thomas Jefferson University
Check if you qualify for this uveal melanoma clinical trial in Philadelphia, PA
If you're searching for uveal melanoma treatment options in Philadelphia, PA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Philadelphia research site is actively enrolling participants for this clinical trial. You'll receive care from experienced uveal melanoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.